Rochlin Kate 4
4 · IN8BIO, INC. · Filed May 7, 2025
Insider Transaction Report
Form 4
IN8BIO, INC.INAB
Rochlin Kate
President and COO
Transactions
- Disposition to Issuer
Series A Warrants (right to buy)
2025-04-27−12,295→ 0 totalExercise: $0.45Exp: 2025-10-04→ Common Stock (12,295 underlying) - Exercise/Conversion
Series A Warrants (right to buy)
2025-04-30−12,295→ 0 totalExercise: $0.18Exp: 2025-05-02→ Common Stock (12,295 underlying) - Exercise/Conversion
Common Stock
2025-04-30$0.18/sh+12,295$2,267→ 55,169 total - Award
Series A Warrants (right to buy)
2025-04-27+12,295→ 12,295 totalExercise: $0.18Exp: 2025-05-02→ Common Stock (12,295 underlying) - Disposition to Issuer
Series B Warrants (right to buy)
2025-04-27−12,295→ 0 totalExercise: $1.50Exp: 2028-12-13→ Common Stock (12,295 underlying) - Award
Series B Warrants (right to buy)
2025-04-27+12,295→ 12,295 totalExercise: $0.45Exp: 2028-12-13→ Common Stock (12,295 underlying)
Footnotes (4)
- [F1]The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025.
- [F2]Fully vested and exercisable.
- [F3]The reported securities are included within 12,295 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 12,295 shares of common stock.
- [F4]The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share.